Search PubMed⌕ Search

Biomedical subjects

B Simon

Publications and source records attributed to B Simon.

At least 343 records · Page 19Linked to original sources
PubMed1981

The new histamine H2-receptor antagonist ranitidine. Duration of action.

The antisecretory effects of a new histamine H2-receptor antagonist, ranitidine hydrochloride, have been investigated on basal and pentagastrin-stimulated acid secretion in healthy volunteers 5 and 10 h after oral administration of 150 mg. In addition, the 24-h intragastric pH-profiles have been measured in patients undergoing parenteral nutrition after three doses of 150 mg ranitidine per day. A 40% inhibition of basal acid output has been noted even 10 h after drug intake. The intragastric pH-values were raised above 5 for at least 24 h. The new H2-antagonist ranitidine has been proven to be a potent and long-acting antisecretory compound.

Adult↗
PubMed1981

A death in the life of a therapist and its impact on the therapy.

Several years ago, each of the authors experienced the death of a close family member. In the months after our return to work, we found ourselves discussing with each other our losses, the process of mourning, our families, and gradually, our patients. We became aware that we both were struggling privately with the problem of being a therapist in the wake of a deep personal loss. We began to discuss our cases in greater detail with each other, reviewed the literature pertinent to upheaval in the lives of therapists, and spoke with colleagues who had also experienced the death of a loved one. This paper explores the problems and opportunities that may arise in this common clinical situation. Our principal finding is that the interaction between patient and therapist often repeats an earlier trauma for the patient in which the therapist unwittingly reenacts a pathogenic parental response. The therapist should be sensitive to this possibility and attempt to deal with the problem interpretively. Rather than focusing on whether or not to reveal his or her loss to the patient, the therapist should address the broader issue of the meaning that revealing or not revealing will have for the patient. Overall, we hope to further the dialogue about the impact of a therapist's loss on the patient.

Adult↗
PubMed1981

Adrenoceptor of the alpha 2-subtype mediating inhibition of the human fat cell adenylate cyclase.

In an attempt to characterize the adenylate cyclase-coupled alpha-adrenoceptors of human fat cells the effects of various alpha-adrenergic agonists and antagonists were examined in the presence of 0.05 mmol/l of propranolol. The order of agonist potencies with respect to alpha-adrenergic inhibition was (-)-adrenaline greater than alpha-methyl-(-)-noradrenaline greater than (-)-phenylephrine with half-maximal inhibition occurring at 2 mumol/l of (-)-adrenaline and 7 mumol/l of alpha-methyl-(-)-noradrenaline respectively. The inhibition of adenylate cyclase induced by 0.05 mmol/l of (-)-adrenaline was reversed by the alpha-blocking agents yohimbine and prazosin, with the alpha 2-site-directed antagonist yohimbine being more than 100-times more potent than prazosin which is more active at alpha 1-sites. The results show that the cyclase-coupled alpha-adrenoceptors of human fat cells, which probably represent the physiologically relevant target of antilipolytic catecholamine effects, display characteristic features of the alpha 2-adrenoceptor subtype.

Adenylyl Cyclases↗
PubMed1981

The new histamine H2-receptor antagonist ranitidine. Duration of action.

The antisecretory effects of a new histamine H2-receptor antagonist ranitidine hydrochloride 150 mg, have been tested on basal and pentagastrin-stimulated acid secretion in healthy volunteers 5 and 10 h after oral administration. In addition, the 24 h intragastric pH-profiles have been measured in patients undergoing parenteral nutrition after three oral doses of ranitidine 150 mg per day. A significant inhibition of basal acid output has been observed up to 10 h after the drug. The intragastric pH remained above 5 for at least 24 h. Ranitidine has proven to be a more potent and longer acting antisecretory compound than cimetidine.

Administration, Oral↗
PubMed1981

Adenylate cyclase of multiple lipomata. Regional differences in adrenaline-responsiveness.

Multiple symmetric lipomatosis has been proposed to be associated with impaired catecholamine-responsiveness of hypertrophic adipose tissue at the level of beta-adrenergic receptors or adenylate cyclase respectively. We have studied the regulation of the adenylate cyclase by guanine nucleotides and adrenaline in 5 subjects suffering from multiple encapsulated lipomata. In the presence of GTP (0.1 mmol/l) basal adenylate cyclase activity averaged 0.5 +/- 0.3 nmol cAMP/mg protein/10 minutes in normal adipose tissue and 1.0 +/- 0.4 nmol cAMP/mg protein/10 minutes in hypertrophic adipose tissue respectively. The synthetic GTP-analogue GMP(PNP) (0.1 mmol/l) increased non-stimulated activity by about 100% in both tissues. Adrenaline (1 mumol/l-1 mmol/l) caused a dose-dependent increase of enzymic activity in both tissues which had a maximum of 130% above basal levels in the presence of GTP and of 300% in the presence of GMP(PNP) respectively. In one of the six subjects suffering from gluteal lipomata normal adipose tissue was obtained from the gluteal as well as the abdominal region on two occasions. Maximally effective concentrations of adrenaline (1 mmol/l) induced a 3-fold increase of enzymic activity in abdominal membranes compared with about a 1.7- and 1.75-fold increase in normal and lipomatous tissue from the gluteal region. The results show that encapsulated lipomata contain a normally reactive adenylate cyclase system.

Adenylyl Cyclases↗
PubMed1981

The speech pathologist and management of children with tracheostomies.

Troublesome airway problems necessitating the presence of a tracheostomy for extended periods of time are now not uncommon in children. To date, little attention has been devoted to the communication problems these young patients encounter. Experience with 44 children with tracheostomies, some of whom are ventilator-dependent, at the Children's Hospital of Philadelphia has enabled us to develop a therapy program that we feel would be useful to other speech professionals treating such patients. The speech pathologist must take an active role in the evaluation and management of these patients and the education of the family and hospital staff. The ultimate goal is to provide communicative and feeding skills to these handicapped children.

Bronchopulmonary Dysplasia↗